Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05549219




Registration number
NCT05549219
Ethics application status
Date submitted
24/08/2022
Date registered
22/09/2022
Date last updated
18/03/2024

Titles & IDs
Public title
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
Scientific title
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDG
Secondary ID [1] 0 0
GLM101-002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pmm2-CDG 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Metabolic and Endocrine 0 0 0 0
Metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GLM101

Experimental: 10 mg/kg GLM101 - GLM101 IV infusions, given weekly

Experimental: 20 mg/kg GLM101 - GLM101 IV infusions, given weekly

Experimental: 30 mg/kg GLM101 - GLM101 IV infusions, given weekly


Treatment: Drugs: GLM101
GLM101 IV Infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate changes in coagulation and antithrombosis factors
Timepoint [1] 0 0
12 weeks and 24 weeks
Primary outcome [2] 0 0
Evaluate changes from baseline in ataxia
Timepoint [2] 0 0
12 weeks and 24 weeks
Secondary outcome [1] 0 0
Significant change in pharmacodynamic activity
Timepoint [1] 0 0
12 weeks and 24 weeks
Secondary outcome [2] 0 0
Number of participants with treatment-emergent adverse events assessed by severity and frequency
Timepoint [2] 0 0
12 weeks and 24 weeks
Secondary outcome [3] 0 0
Maximum observed plasma concentration (Cmax)
Timepoint [3] 0 0
12 weeks and 24 weeks
Secondary outcome [4] 0 0
Time to maximum observed plasma concentration (Tmax)
Timepoint [4] 0 0
12 weeks and 24 weeks
Secondary outcome [5] 0 0
Area under the plasma concentration vs. time curve (AUC)
Timepoint [5] 0 0
12 weeks and 24 weeks

Eligibility
Key inclusion criteria
- Is a male or female, 18 to 65 years of age, inclusive, at Screening; 12-17 years of
age inclusive at Screening or 2-11 years of age, inclusive at Screening

- Has been diagnosed with PMM2-CDG with genetic test confirmation;

- If the participant is a female of childbearing potential, she must not be pregnant
(confirmed by a negative serum pregnancy test), is using a medically accepted method
of contraception (abstinence, a hormonal contraceptive in conjunction with a barrier
method, double-barrier method, or use of an intrauterine device), and must agree to
continue using this method for 30 days after the last infusion of GLM101;

- If the participant is a female of non-childbearing potential, she must be
pre-pubertal, surgically sterile, or must have an ovarian dysfunction confirmed by a
follicle stimulating hormone > 40 IU/L;

- If the participant is a sexually active male with female partners, the sexually
mature, nonsterile male participant agrees to use a medically acceptable method of
contraception (abstinence, the partner taking a hormonal contraceptive in conjunction
with a barrier method, double-barrier method, or use by the partner of an intrauterine
device) and agrees to continue using this method for 30 days after the last infusion
of GLM101. Males are considered surgically sterile if they have undergone bilateral
orchiectomy or vasectomy at least 3 months prior to Screening;

- If the participant is male, he must agree to refrain from donating sperm during the
study and 30 days after the last infusion of GLM101;

- Is willing and able to provide informed consent/assent, directly or through his/her
legally authorized representative.
Minimum age
2 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Diagnosis of congenital disorder of glycosylation (CDG) other than PMM2;

- Has an active infection requiring parenteral antibiotics, antivirals, or antifungals
or treatment with systemic steroids within 7 days prior to Screening;

- Has confirmed active coronavirus disease-2019 (COVID-19) or tests positive for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or check in to the
clinical site;

- ALT or AST >3x ULN and total bilirubin >2x ULN or INR >1.5 (abnormal biological values
of liver function)

- Has a history of a severe allergic reaction to any drug or excipients of GLM101 (as
listed in the GLM101 Investigator's Brochure);

- Has a known history of poor venous access;

- Has a history of liver transplant;

- Has a history of drug or alcohol use disorder within 12 months from Screening;

- Has had a major surgical procedure within 30 days prior to Screening;

- Has Screening or eligibility confirmation laboratory value(s) outside the laboratory
reference range considered clinically significant and not related to PMM2-CDG;

- If female, has a positive serum pregnancy test during Screening;

- Has serology positive for hepatitis B surface antigen or hepatitis C antibody during
Screening;

- Has history or presence, upon clinical evaluation, of any illness that might impact
the safety of GLM101 infusion or evaluability of drug effect based on the
Investigator's and Medical Monitor's discretion;

- Is currently participating in another interventional clinical study or has completed
another clinical study with an investigational drug or device within 30 days or 5
half-lives before GLM101 infusion, except for acetazolamide. Participants may be
enrolled and continue treatment with acetazolamide only if they are on a stable dose
for at least 30 days prior to dosing with GLM101, and the dose remains unchanged for
the duration of the study.

- Weight exceeds 75 kg

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2025
Actual
Sample size
Target
44
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Minnesota
Country [3] 0 0
Spain
State/province [3] 0 0
Barcelona

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Glycomine, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential
pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in
adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The
planned doses of GLM101 to be investigated are 10, 20 and 30 mg/kg. The study will consist of
a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up
Period.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05549219
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Director Clinical Operations
Address 0 0
Country 0 0
Phone 0 0
650-264-7560
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05549219